Our mission is to eradicate mesothelioma as a life-ending
disease.
December 8, 2004
VIA FEDERAL EXPRESS (791998366720) and
TELECOPY (202) 228-1229
Ms. Seema Singh
Legal Counsel
Office of Senator Arlen Specter
711 Hart Building
Washington, D.C. 20510
Re: CDMRP for Navy Veterans Stricken with
Service-Connected Malignant Mesothelioma
Dear Ms. Singh:
Kevin O'Scannlain from Senator Hatch's office has
advised me that you will be the point person on the revised
asbestos trust fund bill (SB 2290). For more than a year,
the Mesothelioma Applied Research Foundation (MARF), has
been working with Senator Hatch's office in our
campaign to create a federally-funded mesothelioma research
and treatment program. We proposed a $140 million
comprehensive research and treatment program, all of which
was adopted in the Ban Asbestos Act, and some of which was
included in Senator Hatch's draft. As Mr.
O'Scannlain said about MARF's modest proposal
juxtaposed against the enormous size of the potential
compensation trust fund: "A $140 million research
program in a $140 billion trust is nothing."
As you go forward, you will be hearing a lot about the
special financial and medical hardships that mesothelioma
patients must endure. Yet my bet is you won't hear much
about any solutions to the medical problem, on either a
patient or a national level. Asbestos Cancer is truly an
epidemic, yet this country has never invested in any
medical research programs on a level proportionate to other
cancers. In the past few years, the National Cancer
Institute has allocated about $2 million per year towards
research, but a large chunk of that has been consumed by
grants that deal principally with causation issues, not
treatment, early detection, or prevention (the NCI's
2004 budget was about $5 billion). Billions have been
gobbled up by litigation, most of which has gone to
transaction costs and fees, and not a dime has been
invested in curing or treating the disease.
The federal government has a duty to fix this national
health problem. Of the 4,000 Americans diagnosed with
mesothelioma every year, approximately 32% were exposed to
asbestos while serving in the U.S. Navy or while working in
naval shipyards. Despite the heavy toll this insidious
cancer exacts on Navy servicemen, neither the Department of
Defense nor the Department of Veterans Affairs has a
medical research and treatment program for mesothelioma.
Since 2000, MARF has united patients, doctors, lawyers and
former asbestos manufacturers in the mission to eradicate
this terrible disease. In conjunction with the Ban Asbestos
Act, we have proposed the creation of a $140 million
Mesothelioma Research and Treatment Program, which would
fund 10 centers of excellence, establish the Admiral Elmo
Zumwalt Registry and the Congressman Bruce Vento Tissue
Bank, among other important programs. However, the need to
fund medical research has always been overshadowed by the
"bigger" issue of whether to compensate victims,
and if so, how much and by whom? The compensation debate
has always trumped the argument for finding a cure. There
is now widespread agreement that the merits of a medical
research program for asbestos cancer should be considered
separately from the rancorous debate over the merits of
asbestos civil litigation tort reform.
We are asking for your cooperation in our mission to
persuade Congress to create a Congressionally Directed
Medical Research Program for Mesothelioma (CDRMP). Congress
has created CDMRPs for ovarian, prostate, breast and other
cancers which are not necessarily service-connected. From
1992 to 2005, Congress has appropriated over $3.4 billion
dollars to the DOD for specific research priorities. The
time is long overdue for Congress to recognize the service
and sacrifice of the thousands of veterans who either
currently suffer from an asbestos-related cancer or are at
a substantial risk for contracting same in the future.
We would like to discuss our proposal with you. We envision
a united front that includes the DVA and the DOD, along
with distinguished members of the scientific, medical,
business and legal communities. The creation of a federal
program for mesothelioma research should not be tied to the
success or failure of asbestos compensation reform
legislation. With your support, we can attract support from
both sides of the aisle, as mesothelioma does not respect
party, rank, or title.
For your review, we are attaching a number of memoranda,
letters and articles which speak to MARF's history,
purpose and our impact within the medical and legal
communities. The attachments include a roadmap for curing
mesothelioma, a draft of the proposed $140 million
research and treatment program, a summary of the grants funded by MARF,
an overview of MARF's peer-review funding
mechanism, an article that discusses the options for marshalling the
resources to fund medical research, and a
statement by a Navy veteran afflicted with
mesothelioma.
We will be calling you in the next few days to discuss this
letter and the next step. We look forward to collaborating
with you and your staff.
Sincerely,
Roger G. Worthington
Founding Director
Enclosures